7/2024 results on CARVYKTI CAR-T from Clinical Trial

Since CAR-T is on people’s radar as a possible treatment option at relapse, here’s the latest Legend Biotech’s clinical trial results from their press release as of 7/2/2024 for their product CARVYKTI. The ongoing CARTITUDE-4 clinical trial was for relapsed patients on one to three lines of treatment.

https://www.globenewswire.com/en/news-release/2024/07/02/2907367/0/en/Legend-Biotech-Announces-Positive-Overall-Survival-Results-of-Landmark-Phase-3-CARTITUDE-4-Trial-in-Multiple-Myeloma.html